Pancreatic ductal adenocarcinoma immune microenvironment and immunotherapy prospects

Chronic Diseases and Translational Medicine. 2020;6(1):6-17

 

Journal Homepage

Journal Title: Chronic Diseases and Translational Medicine

ISSN: 2095-882X (Print)

Publisher: KeAi

Society/Institution: Chinese Medical Association

LCC Subject Category: Medicine: Medicine (General)

Country of publisher: China

Language of fulltext: English

Full-text formats available: PDF, HTML

 

AUTHORS


Ke-Yu Li (Department of Pancreatic Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China; Department of Oncology, Sidney Kimmel Cancer Center at Johns Hopkins University School of Medicine, Baltimore, MD, 21231, USA)

Jia-Long Yuan (School of Basic Medical Science, Capital Medical University, Beijing 100069, China)

Diego Trafton (Department of Oncology, Sidney Kimmel Cancer Center at Johns Hopkins University School of Medicine, Baltimore, MD, 21231, USA)

Jian-Xin Wang (Department of Oncology, Sidney Kimmel Cancer Center at Johns Hopkins University School of Medicine, Baltimore, MD, 21231, USA; Department of Hepatic-biliary-pancreatic Surgery, First Affiliated Hospital of Zhejiang University, Hangzhou, Zhejiang 310000, China)

Nan Niu (Department of Oncology, Sidney Kimmel Cancer Center at Johns Hopkins University School of Medicine, Baltimore, MD, 21231, USA; Department of Gastrointestinal and Pancreatic Surgery, Zhejiang Provincial People's Hospital, Hangzhou, Zhejiang 310014, China)

Chun-Hui Yuan (Department of General Surgery, Peking University Third Hospital, Beijing 100191, China)

Xu-Bao Liu (Department of Pancreatic Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China)

Lei Zheng (Department of Oncology, Sidney Kimmel Cancer Center at Johns Hopkins University School of Medicine, Baltimore, MD, 21231, USA; Corresponding author. Department of Oncology, Sidney Kimmel Cancer Center at Johns Hopkins University School of Medicine, 1650 Orleans Street, CRB1, Rm 351, Baltimore, MD, 21231, USA. Fax: +1 (410) 614 8216.)

EDITORIAL INFORMATION

Double blind peer review

Editorial Board

Instructions for authors

Time From Submission to Publication: 35 weeks

 

Abstract | Full Text

The tumor microenvironment of pancreatic ductal adenocarcinoma (PDAC) is non-immunogenic, which consists of the stellate cells, fibroblasts, immune cells, extracellular matrix, and some other immune suppressive molecules. This low tumor perfusion microenvironment with physical dense fibrotic stroma shields PDAC from traditional antitumor therapies like chemotherapy and various strategies that have been proven successful in other types of cancer. Immunotherapy has the potential to treat minimal and residual diseases and prevent recurrence with minimal toxicity, and studies in patients with metastatic and nonresectable disease have shown some efficacy. In this review, we highlighted the main components of the pancreatic tumor microenvironment, and meanwhile, summarized the advances of some promising immunotherapies for PDAC, including checkpoint inhibitors, chimeric antigen receptors T cells, and cancer vaccines. Based on our previous researches, we specifically discussed how granulocyte-macrophage colony stimulating factor based pancreatic cancer vaccine prime the pancreatic tumor microenvironment, and introduced some novel immunoadjuvants, like the stimulator of interferon genes. Keywords: Pancreatic ductal adenocarcinoma, Tumor microenvironment, Immunotherapy, Cancer vaccine, Stimulator of interferon genes